John Johnson, a director at Xeris Biopharma Holdings, Inc. (XERS), executed a series of stock transactions on June 4, 2026, involving both the sale and acquisition of company shares. These movements in insider ownership were reported in conjunction with the biopharmaceutical company's recent financial disclosures and market performance.
On the specified date, Mr. Johnson sold 15,000 shares of Xeris Biopharma's common stock. The transaction resulted in a total value of $91,422. The shares were sold at a weighted average price of $6.0948 per share, with individual transaction prices fluctuating between $5.970 and $6.170. This sale was facilitated through a Rule 10b5-1 trading plan that Mr. Johnson had adopted on August 13, 2025. Following the execution of this sale, Mr. Johnson's direct holdings in the company's common stock stood at 683,083 shares.
Concurrently with the sale, Mr. Johnson acquired additional equity in Xeris Biopharma. He received 24,193 shares of common stock through a restricted stock unit (RSU) grant. These shares were issued under the company’s 2018 Stock Option and Incentive Plan and represent a contingent right to receive one share of common stock per unit. The vesting of these shares is scheduled to occur in full upon the earlier of June 4, 2026, or the date of the company’s next annual meeting of stockholders, contingent upon Mr. Johnson's continued service through the vesting date. Following this acquisition, his direct ownership of common stock increased to 707,276 shares.
Furthermore, Mr. Johnson was granted 32,996 stock options. These options provide the right to purchase an equivalent number of common stock shares at an exercise price of $6.15 per share. Also granted under the 2018 Plan, these stock options have an expiration date of June 4, 2036. Similar to the RSUs, the stock options will vest in full upon the earlier of June 4, 2026, or the date of the company’s next annual meeting of stockholders, subject to continued service. After this grant, Mr. Johnson directly holds 32,996 stock options.
The insider activity occurs as Xeris Biopharma trades near $6.18, reflecting a market capitalization of approximately $1.06 billion. Market analysis indicates that the stock appears undervalued at current levels, positioning it among opportunities on the Most Undervalued list. The company has exhibited strong fundamentals, including revenue growth of 41% over the last twelve months and a gross profit margin of 86%.
Financially, Xeris Biopharma reported robust results for the first quarter of 2026. The company achieved a 38% increase in total revenue compared to the previous year, reaching $83.1 million. Although this revenue figure slightly missed forecasts, Xeris Biophama exceeded earnings expectations with an earnings per share (EPS) of $0.01. These results indicate a strong performance for the company in the recent period.
There have been no recent mergers or acquisitions involving Xeris Biopharma. Additionally, there were no significant analyst upgrades or downgrades reported for the company. Investors and analysts are likely to closely monitor Xeris Biopharma’s future performance following these developments.
Key Points:
- Insider Transactions: Director John Johnson sold 15,000 shares under a Rule 10b5-1 plan and acquired 24,193 RSU shares plus 32,996 stock options, reflecting ongoing engagement with the company's equity structure.
- Financial Performance: Xeris Biopharma reported a 38% year-over-year revenue increase to $83.1 million in Q1 2026, with EPS of $0.01 exceeding expectations despite slightly missing revenue forecasts.
- Market Valuation: The stock trades near $6.18 with a market cap of $1.06 billion, with analysis suggesting undervaluation relative to strong fundamentals including an 86% gross profit margin and 41% revenue growth over the last twelve months.
Risks and Uncertainties:
- Revenue Forecast Miss: While EPS exceeded expectations, the company's Q1 revenue slightly missed forecasts, indicating potential volatility in revenue projections within the biopharmaceutical sector.
- Vesting Conditions: The vesting of both RSUs and stock options is contingent upon continued service and specific dates, introducing uncertainty regarding the actual realization of equity value for the director.
- Market Perception: Despite strong fundamentals, the stock's undervaluation status suggests ongoing market skepticism or external pressures affecting the biopharmaceutical market, requiring close monitoring of future performance indicators.